Advanced in Polymyalgia Rheumatica

Xavier Mariette

Paris, FR 
Advanced in Polymyalgia Rheumatica
Paris, FR 
OverviewLocationsClinical Research

Overview

Xavier Mariette practices in Paris, France. Mr. Mariette is rated as an Advanced expert by MediFind in the treatment of Polymyalgia Rheumatica. His top areas of expertise are Dry Mouth, Sjogren Syndrome, Dry Eye Syndrome, and Rheumatoid Arthritis (RA).

His clinical research consists of co-authoring 515 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Polymyalgia Rheumatica.

Gender
Male

Locations

Paris, France
Other Locations
Le Kremlin Bicetre, France
Villejuif, France
Le Plessis, France
Gif-sur-yvette, France
Raray, France
Fontenay-sous-bois, France
Orsay, France
Chatenay-sur-seine, France
INSERM U1184, Rue Gabriel Peri, Peri, 94270, France
INSERM U1012, 371 Avenue Du Doyen G. Giraud, 34295 Montpellier Cedex 5, Montpellier, 34295, France
Inserm U1012, 78 Rue Du Général Leclerc, Rouez, 94278, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment Period, to Evaluate the Maintenance of Treatment Effect of Ixekizumab (LY2439821) in Patients With Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Drug
Study Phase: Phase 3
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Comparison of Humoral Response to Conjugate Pneumococcal Vaccine and Polysaccharide Pneumococcal Vaccine in Rheumatoid Arthritis (RA) Patients Treated With Abatacept
Enrollment Status: Completed
Publish Date: January 03, 2022
Intervention Type: Biological, Drug
Study Phase: Not Applicable
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: August 09, 2021
Intervention Type: Drug
Study Phase: Phase 4
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Lead Time of the Methotrexate Establishment and Vaccinal Protection Against the Pneumococcal Agent in Patients Affected With Rheumatoid Polyarthritis
Enrollment Status: Completed
Publish Date: August 03, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

512 Total Publications

Cutaneous Vasculitis in Primary Sjögren Disease.
Cutaneous Vasculitis in Primary Sjögren Disease.
Journal: JAMA dermatology
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mariette's expertise for a condition
ConditionClose
View All 14 Advanced Conditions
View All 92 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile